The Danish pharmaceutical companyNew Nordiskstarted selling the pill version of the drugWegovyus Estados Unidos this Monday, January 5, 2026. The product, approved by the FDA in December 2025, offers starting doses of 1.5 mg and 4 mg at $149 per month for patients who pay directly.
This oral option represents the first GLP-1 pill authorized specifically for chronic weight management in adults with obesity or overweight and associated comorbidities. The company is preparing production at its facilities in Carolina of Norte to meet initial demand.
The Wegovy tablet contains semaglutide, the same active ingredient as the weekly injectable version, already established on the market. Pacientes should take the pill daily on an empty stomach, with water, and wait 30 minutes before eating or taking other medications.
- Average weight reduction of up to16.6%in 64 weeks, according to the OASIS 4 clinical trial with 307 participants.
- Efficacy comparable to the 2.4 mg injection, with about a third of patients losing 20% or more of their body weight.
- Additional indication for reducing major cardiovascular risks in adults with established disease.
Advantages of the oral formula
The pill offers greater convenience for those who avoid injections, expanding access to treatment. Especialistas highlight that the oral form facilitates long-term adherence and attracts patients who were hesitant with the injectable version.
Novo Nordisk positions the product as an affordable alternative, with reduced initial prices for direct payments. Doses higher doses, such as 9 mg and 25 mg, will be available by the end of the week, with prices adjusted to US$199 or US$299 per month in some cases.
Scale production avoids initial shortages seen with the injectable version years ago. The company reinforces its stock to quickly supply American pharmacies.
Detailed clinical results
The phase 3 OASIS 4 trial demonstrated an average weight loss of 16.6% with full adherence to 25 mg daily treatment. Participantes in the placebo group recorded a reduction of just 2.7%.
More than 76% of pill users achieved a loss of at least 5% of their initial weight. The safety profile remains consistent with previous studies of semaglutide, including common but manageable gastrointestinal effects.
The approval is also based on the SELECT trial, which confirmed cardiovascular benefits. The pill reduces the risk of events such as heart attack, stroke or death in patients with obesity and established heart disease.
Pricing strategy
Novo Nordisk adopts a hybrid model, with discounts for direct payments and negotiations with insurance companies. Initial Doses at US$149 aims to attract consumers without full coverage.
The approach differs from the traditional standard, focused on health plan reimbursements. The company seeks to expand the self-payment segment, which is growing in the LPG-1 market.
Analysts expect the pill to attract new users and boost Novo Nordisk’s recovery from challenges in 2025. Competition with rivals like Eli Lilly remains intense, but leadership in the oral option gives it an early advantage.
Availability and administration
The pill should be taken in the morning, on an empty stomach, for maximum absorption. Não requires refrigeration, unlike the injectable version, making storage and transport easier.
American pharmacies receive the first shipments this week. Novo Nordisk monitors distribution to ensure broad access from launch.
Interested patients consult doctors for evaluation and appropriate prescription. Treatment is always combined with a reduced calorie diet and increased physical activity.
Obesity Drugs Market
The LPG-1 segment projects exponential growth, with estimates of billions in annual global sales. The introduction of oral options accelerates adoption in diverse populations.
Obesity affects millions in the Estados Unidos, with rates stable at around 37% of the adult population in 2025. Effective Tratamentos such as Wegovy contribute to the gradual reductions observed recently.
Novo Nordisk submits the pill for approval in other regions, including Europa via EMA. Decisões additional regulatory requirements may expand global availability throughout 2026.
